SLC39A6

Across TCGA pan-cancer cohorts, SLC39A6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC39A6 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC39A6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC39A6 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where SLC39A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.293	0.513	<.001	69	view →
HNSC	DFS	Tertile	IV	0.604	0.960	.002	28	view →
CCRCC	OS	Quartile	III,IV	0.596	1.000	.034	4	view →
LSCC	DFS	Tertile	All	0.219	0.853	.010	4	view →
GBM	OS	Median	All	0.495	0.290	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC39A6–PDAC (DFS)

Open the PDAC breakdown →